Today: 8 June 2026
Browse Category

NASDAQ:VRAX 18 May 2026 - 19 May 2026

Why Virax Biolabs Stock Is Jumping Before the Bell Today

Why Virax Biolabs Stock Is Jumping Before the Bell Today

Virax Biolabs shares jumped in pre-market trading Monday, indicated at $0.3458 after closing Friday at $0.1535. The move followed a sponsored TV segment featuring CEO James Foster and a new SEC filing showing Armistice Capital holds 4.99% of shares. ViraxImmune, the company’s main test, remains in development and is not approved for diagnostic use. No new company press release appeared over the weekend.
18 May 2026
·

Stock Market Today

  • Altimeter Capital CEO Warns Traders on Potential Risks Ahead of SpaceX IPO
    June 8, 2026, 9:46 AM EDT. Brad Gerstner, CEO of Altimeter Capital, cautioned retail investors about challenges in upcoming big tech IPOs, including the anticipated SpaceX public offering. Gerstner highlighted that these initial public offerings (IPOs) could pose risks due to market volatility and heightened investor scrutiny. His warning signals the need for careful analysis as SpaceX, a major space exploration and satellite internet company, prepares to enter public markets. Investors are advised to stay alert amid these developments to navigate potential pitfalls.

Latest articles

Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
Go toTop